Results 141 to 150 of about 3,861 (173)
Some of the next articles are maybe not open access.
A Randomized, Crossover Design Study of Sevelamer Carbonate Powder and Sevelamer Hydrochloride Tablets in Chronic Kidney Disease Patients on Haemodialysis. [PDF]
Nephrology Dialysis Transplantation, 2009 Background. Sevelamer carbonate is an improved, buffered form of sevelamer hydrochloride developed for the treatment of hyperphosphataemia in CKD patients.
Philip Kalra +2 more
exaly +2 more sources
Nephron Clinical Practice, 2004
Hyperphosphataemia in patients with chronic renal failure has traditionally been treated with calcium- and aluminium-containing phosphate binders. This article briefly discusses the rationale and complications of these treatments and reviews sevelamer that is a novel non-calcium-, non-aluminium-containing phosphate binder and the evidence to support ...
Jane, Henderson, Paul, Altmann
openaire +2 more sources
Hyperphosphataemia in patients with chronic renal failure has traditionally been treated with calcium- and aluminium-containing phosphate binders. This article briefly discusses the rationale and complications of these treatments and reviews sevelamer that is a novel non-calcium-, non-aluminium-containing phosphate binder and the evidence to support ...
Jane, Henderson, Paul, Altmann
openaire +2 more sources
Annals of Pharmacotherapy, 2010
OBJECTIVE To review the pharmacology, pharmacokinetics, clinical efficacy, safety data, and place in therapy of sevelamer carbonate for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD).
Mary M, Barna +2 more
openaire +2 more sources
OBJECTIVE To review the pharmacology, pharmacokinetics, clinical efficacy, safety data, and place in therapy of sevelamer carbonate for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD).
Mary M, Barna +2 more
openaire +2 more sources
Pediatric Blood and Cancer, 2008 Background. Sevelamer is a phosphate-binder used effectively for the treatment of hyperphosphatemia in patients treated with dialysis. Objectives. To describe the safety of sevelamer in children with hyperphosphatemia secondary to tumor lysis syndrome ...
Lee Dupuis, Manuel Diezi, Lillian Sung
exaly +2 more sources